Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06649253 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse

Study acronym: REALL CD9
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Start date changed from estimate of Apr 2025 to Mar 22, 2025
    • Site contacts updated at 3 of 3 sites
    v4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date: Feb 2025 to Apr 2025
    • Primary completion date: Feb 2035 to Apr 2035
    • Study completion date: Jun 2035 to Apr 2035
    • Site details revised at 3 of 3 sites
  4. Start date: Nov 2024 to Feb 2025
    • Primary completion date: Nov 2034 to Feb 2035
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Trial Details
NCT Number NCT06649253
Lead Sponsor Rennes University Hospital
Conditions
(from sponsor)		 Leukemia, Lymphoblastic, Acute, Pediatric
Related terms Leukemia
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov